Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL11315262 | 0.73 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL4364308 | 0.71 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL6118333 | 0.65 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL6298450 | 0.65 | HSD17B10 (0.45) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL406704 | 0.63 | RAB9A (0.47) | ALDH1A1SMN1; SMN2LMNAHSD17B10CYP3A4 | |
| SCHEMBL17281511 | 0.60 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL1913695 | 0.59 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL7775817 | 0.59 | NSD1 (0.53) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL8383088 | 0.59 | NSD1 (0.68) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 | |
| SCHEMBL21091722 | 0.57 | CYP3A4 (0.57) | ALDH1A1SMN1; SMN2LMNAHSD17B10PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-20230310358-A1 | Compositions And Methods For Treating Autism | YAMO PHARMACEUTICALS LLC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-114901272-A | Sustained release preparation | 霍夫曼技术有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2022-07-07 | — | — | US | disclosed |
| EP-3955910-A1 | SUSTAINED RELEASE FORMULATIONS | Hoffman Technologies LLC. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210338619-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | YAMO PHARMACEUTICALS LLC | 2021-11-04 | — | — | US | disclosed |
| EP-3823593-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3823626-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4170654-A | Antihypertensive compositions containing N-heterocyclicalanines and α- | MERCK & CO., INC. (US) | 1979-10-09 | — | — | US | disclosed |
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4156734-A | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid | MERCK & CO., INC. (US) | 1979-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310358-A1 | Compositions And Methods For Treating Autism | MECP2, AADAT, CHAT | ALDH1A1 878/4885SMN1; SMN2 1292/4885LMNA 3609/4885 |
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | TH, PAH, COMT | ALDH1A1 307/4885SMN1; SMN2 1428/4885LMNA 4718/4885 |
| US-20210338619-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | MECP2, AADAT, CHAT | ALDH1A1 876/4885SMN1; SMN2 1214/4885LMNA 3774/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | ALDH1A1 100/4885SMN1; SMN2 1953/4885LMNA 3547/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | ALDH1A1 114/4885SMN1; SMN2 793/4885LMNA 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.